Zacks Investment Research upgraded shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) from a hold rating to a strong-buy rating in a report issued on Wednesday, Zacks.com reports. The firm currently has $7.25 target price on the biotechnology company’s stock.

According to Zacks, “Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada. “

APTO has been the subject of a number of other research reports. Piper Sandler began coverage on shares of Aptose Biosciences in a research report on Thursday, January 9th. They set an overweight rating and a $10.00 price objective for the company. ValuEngine upgraded shares of Aptose Biosciences from a sell rating to a hold rating in a report on Tuesday, December 10th. Finally, BidaskClub upgraded shares of Aptose Biosciences from a hold rating to a buy rating in a report on Tuesday, December 24th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of Buy and an average target price of $6.88.

Aptose Biosciences stock traded up $0.03 during trading hours on Wednesday, reaching $6.24. 19,465 shares of the stock were exchanged, compared to its average volume of 1,136,811. The stock has a market cap of $471.88 million, a P/E ratio of -11.12 and a beta of 2.03. The company has a debt-to-equity ratio of 0.04, a quick ratio of 7.83 and a current ratio of 7.83. Aptose Biosciences has a 52-week low of $1.57 and a 52-week high of $6.66. The firm’s 50 day moving average is $5.00 and its 200 day moving average is $3.05.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last announced its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.12) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.01. Equities research analysts expect that Aptose Biosciences will post -0.55 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in APTO. Point72 Asset Management L.P. purchased a new position in shares of Aptose Biosciences in the 2nd quarter valued at about $5,742,000. Man Group plc purchased a new position in Aptose Biosciences during the 2nd quarter valued at about $3,867,000. P.A.W. Capital Corp purchased a new position in Aptose Biosciences during the 3rd quarter valued at about $1,043,000. Creative Planning purchased a new position in Aptose Biosciences during the 3rd quarter valued at about $156,000. Finally, Morgan Stanley increased its holdings in Aptose Biosciences by 20.7% during the 2nd quarter. Morgan Stanley now owns 315,521 shares of the biotechnology company’s stock valued at $824,000 after acquiring an additional 54,200 shares in the last quarter. Institutional investors and hedge funds own 19.77% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Recommended Story: Bid-Ask Spread

Get a free copy of the Zacks research report on Aptose Biosciences (APTO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Aptose Biosciences (NASDAQ:APTO)

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.